STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
49
13F, latest reported quarter
What the filings say about BPRN
Insiders, 180 days
-$24.7K net sold
2 buyers · 3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$411.7K
1 notice
Princeton Bancorp insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Princeton Bancorp, Inc. insiders sold a net $24.7K of stock across 110 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
79 earlier Form 4 trades (code P or S) here by this insider (78 buys, 1 sale), the last on Nov 20, 2025.
+6.7% median (+6.2% mean) 90-day return after 30 previous buys.
The trade is 43.6% of the 24,138 shares held after it.
No other insider bought within 30 days.
49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director TUCHMAN MARTIN bought about $452.7K of BPRN on Aug 12, 2026, the largest insider purchase at the company since 2025; 49 funds added in the latest 13F quarter.
3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on May 28, 2026.
1 other insider sold within 30 days.
49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Information Officer Clark Matthew T. sold about $59.9K of BPRN on Aug 6, 2026; 1 other insider sold within 30 days and 49 funds added in the latest 13F quarter.
2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 8, 2025.
The trade is 10.5% of the 83,220 shares held after it.
1 other insider sold within 30 days.
49 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Distler Stephen sold about $364.0K of BPRN on Jul 31, 2026, the largest insider sale at the company since 2025; 1 other insider sold within 30 days and 49 funds added in the latest 13F quarter.
Nobody has filed for crossing 5%. That is a fact, not missing data.
BPRN planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Distler Stephen
Filed 2026-07-31
$411.7K
BPRN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Royce Capital Fund - Small-Cap Portfolio
$2.4M position · as of 2026-06-30
1.3%
Royce Small-Cap Value Fund
$1.4M position · as of 2026-06-30
1.3%
Ultra-Small Company Fund
$273.7K position · as of 2026-06-30
0.3%
Ultra-Small Company Market Fund
$378.7K position · as of 2026-06-30
0.3%
Transamerica Small Cap Value
$117.5K position · as of 2026-07-31
0.1%
Omni Small-Cap Value Fund
$853.1K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Dietzler
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.3M
$1.6M
$795.8K
+13%
n/a
2024
$1.4M
$1.7M
$818.9K
+12%
n/a
2023
$1.5M
$2.0M
$848.1K
+17%
n/a
2022
$1.3M
$1.6M
$787.6K
+43%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $24.7K sold by insiders over 180 days, 49 funds added last quarter, $411.7K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM BPRN
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM BPRN
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Single quarter
Free cash flow, TTM
$23.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM BPRN
FY Dec 2025
$20.6M
FY Dec 2024
$13.2M
FY Dec 2023
$21.4M
FY Dec 2022
$23.4M
FY Dec 2021
n/a
Jun 2026
$1.8M
Mar 2026
$4.9M
Dec 2025
$12.0M
Sep 2025
$4.7M
Jun 2025
$2.9M
Mar 2025
$1.1M
Dec 2024
$3.8M
Sep 2024
$766.0K
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2025-09-30 (9 months older than the period end); equity 2026-06-30
Debt to equity BPRN
FY Dec 2025
0.00x
FY Dec 2024
0.00x
FY Dec 2023
0.00x
FY Dec 2022
0.05x
FY Dec 2021
0.00x
Jun 2026
0.00x
Mar 2026
0.00x
Dec 2025
0.00x
Sep 2025
0.00x
Jun 2025
0.04x
Mar 2025
0.00x
Dec 2024
0.00x
Sep 2024
0.00x
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt BPRN
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
2.40x
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
1.00x
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+9.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity BPRN
FY Dec 2025
+7.0%
FY Dec 2024
+4.1%
FY Dec 2023
+11.2%
FY Dec 2022
+12.1%
FY Dec 2021
n/a
Jun 2026
+9.5%
Mar 2026
+7.2%
Dec 2025
+7.0%
Sep 2025
+6.7%
Jun 2025
+2.7%
Mar 2025
+4.4%
Dec 2024
+4.1%
Sep 2024
+4.2%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+1.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets BPRN
FY Dec 2025
+0.8%
FY Dec 2024
+0.5%
FY Dec 2023
+1.5%
FY Dec 2022
+1.6%
FY Dec 2021
n/a
Jun 2026
+1.2%
Mar 2026
+0.9%
Dec 2025
+0.8%
Sep 2025
+0.8%
Jun 2025
+0.3%
Mar 2025
+0.5%
Dec 2024
+0.5%
Sep 2024
+0.5%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital BPRN
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed BPRN
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
11.83x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing BPRN
FY Dec 2025
12.80x
FY Dec 2024
21.79x
FY Dec 2023
8.91x
FY Dec 2022
7.72x
FY Dec 2021
n/a
Jun 2026
10.01x
Mar 2026
11.85x
Dec 2025
12.80x
Sep 2025
12.25x
Jun 2025
31.48x
Mar 2025
18.29x
Dec 2024
21.79x
Sep 2024
22.83x
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no cash line filed
Enterprise value BPRN
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+7.7%
TTM free cash flow over market value at close 2026-10-27
FCF yield BPRN
FY Dec 2025
+8.8%
FY Dec 2024
+5.6%
FY Dec 2023
+9.5%
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
+9.0%
Mar 2026
+10.7%
Dec 2025
+8.8%
Sep 2025
+5.7%
Jun 2025
+4.0%
Mar 2025
+4.5%
Dec 2024
+5.6%
Sep 2024
+5.2%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.04x
P/E over trailing EPS growth of 291%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing BPRN
FY Dec 2025
0.18x
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
0.03x
Mar 2026
0.17x
Dec 2025
0.18x
Sep 2025
0.20x
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
BPRN ranks highest on financial health (99th percentile) and risk and compliance (70th), and lowest on institutional and government (21st), among Banks peers.
Profitability
48
Inputs
Return on equity+9.5% · 41 pct, sector of 327
Return on assets+1.2% · 56 pct, sector of 334
Return on invested capitalfewer than four consecutive quarters of operating income
Return on capital employedfewer than four consecutive quarters of operating income
Financial health
100
Inputs
Debt to equity0.00x · 100 pct, sector of 229
Cash flow to debtno debt to cover
Insider conviction
69
Inputs
Net Form 4 buying (codes P and S), 180d-$25K · 65 pct, sector of 273
Insider buyers, 180d2 · 72 pct, sector of 273
Institutional and government
21
Inputs
Funds adding, latest quarter49 · 21 pct, sector of 257
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
70
Inputs
Short interest, % of float+1.3% · 70 pct, sector of 374
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Growth, US patents
Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BPRN filings, in plain words
Are Princeton Bancorp insiders buying or selling BPRN?
In the 180 days to 2026-10-28, Princeton Bancorp insiders were net sellers, a net $24.7K: $455.3K of purchases and $480.0K of sales reported on Form 4, by 2 buyers and 3 sellers.
Are there planned insider sales of BPRN?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $411.7K of stock; the latest, by Distler Stephen, was filed 2026-07-31.
Read the full summary
In the 180 days to 2026-10-28, Princeton Bancorp insiders were net sellers of BPRN, a net $24.7K across purchases and sales reported on Form 4 by 2 buyers and 3 sellers. Most of that figure, $452.7K, came from a holder of 10% or more rather than an officer or director. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $411.7K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.